Results 221 to 230 of about 2,671,914 (293)
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
British Journal of Pharmacology, EarlyView.This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays. [PDF]
Front Immunol, 2019 Navas A +7 more
europepmc +1 more source
Targeting KRAS for cancer therapy
British Journal of Pharmacology, EarlyView.In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia +4 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Cancer Science, EarlyView.A rapid and efficient CRISPR‐mediated gene editing platform for TIL engineering identified FAM84B as a novel potential target to enhance antitumor activity and pioneered the use of CBE to generate FAM84B loss‐of‐function TIL with enhanced antitumor activity.
Fenge Li +13 more
wiley +1 more source
Cancer Science, EarlyView.Koumine binds IGF2BP3 and promotes its proteasomal degradation, reducing m6A on EED mRNA, accelerating EED decay, lowering H3K27me3, and promoting IRF transcription, thereby restoring MHC‐I and enhancing CD8+ T cell killing. ABSTRACT Resistance to immune checkpoint blockade in gastric cancer often arises from defective antigen presentation due to MHC‐I
Qiu Hongqiang +10 more
wiley +1 more source
Advances in Spatial Heterogeneity and Cellular Localization Specificity of Intratumoral Bacteria
Cancer Science, EarlyView.Spatial localization of intratumoral bacteria governs their functional roles in tumor progression, metastasis, and treatment responses, with guiding significance for clinical management, as reviewed across three spatial paradigms. ABSTRACT Bacteria in tumors are increasingly recognized to be a part of the tumor microenvironment and their biological ...
Minlan Ren +11 more
wiley +1 more source
Cancer Science, EarlyView.A20 suppresses IFN‐γ signaling in HCC cells by binding to STAT1 through its ZnF7 domain, thereby reducing CXCL9, CXCL10, and HLA‐ABC expression, ultimately impairing CD8+ T‐cell‐mediated anti‐tumor immunity. ABSTRACT Immune checkpoint blockade (ICB) has demonstrated efficacy in clinical cancer therapy; however, a significant proportion of cancer ...
Yanlei Dong +14 more
wiley +1 more source